Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Glowing bacteria show researchers how an anti-flu-virus drug may prevent bacterial pneumonia

10.03.2003


Viral enzyme ’clear cuts’ forest of protective molecules on lung cells in mice; blocking that enzyme reduces illness and incidence of death from subsequent infection by Streptococcus pneumoniae



Investigators at St. Jude Children’s Research Hospital have shown in mice how the potentially deadly cooperation between influenza virus and bacterial pneumonia infections can be foiled, even if treatment is delayed and flu virus levels in the lung have peaked.

The St. Jude team showed that the flu virus enzyme neuraminidase (NA) strips lung cells of their protective forest of molecules called sialic acid. The unprotected cells are then vulnerable to subsequent infection with Streptococcus pneumoniae bacteria. But treatment of the mice with the NA-inhibitor drug ostelamivir blocked the activity of flu virus NA and offered significant protection against pneumonia. The study’s findings appear in the March 15 issue of the Journal of Infectious Diseases.


"We previously showed that when Streptococcus pneumoniae was given to mice seven days after they had been infected with flu virus, the mortality was extremely high," said Jonathan McCullers, MD, the lead author of the report. "Our current study using tissue in lab dishes, as well as live mice, showed that viral NA is the key to this deadly synergy between flu virus and pneumonia bacteria. The streptococcus bacteria also have NA," McCullers said, "but it is much less efficient than the viral enzyme in cutting away at the lung cell’s sialic acid barrier."

The St. Jude finding is important because a combined infection with influenza and pneumonia is the sixth leading cause of all deaths worldwide, and is the top cause of death due to an infection, according to McCullers assistant member in the Department of Infectious Diseases at St. Jude. Moreover, the overall death rate associated with pneumonia and influenza increased by 59% between 1979 and 1994, according to a 1996 report in the Journal of the American Medical Association.

"The flu virus targets the sialic acid molecules on the lung cell membrane surface so it can get inside the lung cell and reproduce," McCullers said. "After the virus multiplies inside the cell, the new viruses cut through the sialic acid on the way out."

"By blocking the virus NA we protect the sialic acid molecules covering the lung cells," says McCullers. "That leaves the pneumonia bacteria stranded outside the cells and gives the immune system time to destroy them before they can cause respiratory disease."

In the study, one group of mice received prophylactic (protective) doses of oseltamivir for five days, beginning four hours before being infected with flu virus. Another group got oseltamivir for five days starting 48 hours after being infected with flu.

Mice that received delayed treatment lost weight and had greatly increased levels of virus in their lungs by the time they received oseltamivir. However, these mice still had significant protection against subsequent infection by streptococcus bacteria compared to control mice that received no treatment.

"The key to significantly reducing the rate of death in these mice was not reducing virus levels or maintaining weight," McCullers explains. "What was important was blocking the virus NA enzyme with oseltamivir and preserving the protective sialic acid molecules."

The St. Jude team also studied the effect of oseltamivir on bacterial pneumonia using live mice infected with genetically modified streptococcus. These modified bacteria were engineered to carry on a light-producing chemical reaction--the same chemical reaction used by fireflies. The light, too faint for humans to see, passed through the skin of the mice and was picked up by a special camera.

In mice given flu virus and then the "glowing" streptococcus but no oseltamivir, the camera captured images of extensive bacterial infections throughout the thorax--the part of the body containing the lungs. In mice that also received oseltamivir as a delayed treatment after infection with flu virus, the light emitted from the lungs was less intense and not localized in specific areas. This suggested that the immune system of the infected mice was able to kill many of the bacteria that were "stranded" outside the cell membrane in oseltamivir-treated animals.

Untreated mice developed pneumonia earlier than treated mice and died. In treated mice, even when infection spread, the progression of the disease was slower than in untreated mice, and up to half of the treated animals survived.

When the researchers studied the effect of oseltamivir using human lung cells in a dish, they found that the drug blocked the binding of streptococcus to these cells by interfering with NA, similar to the findings in mice.

The article’s co-author is Rhodes College pre-med student Kimberly A. Bartmess, who works in Dr. McCullers’ lab as a part of the St. Jude – Rhodes Summer Plus Program.


###
This project was supported by the National Institute of Allergy and Infections Diseases at the National Institutes of Health, a Cancer Center Support Grant and ALSAC.

St. Jude Children’s Research Hospital
St. Jude Children’s Research Hospital, in Memphis, Tennessee, was founded by the late entertainer Danny Thomas. The hospital is an internationally recognized biomedical research center dedicated to finding cures for catastrophic diseases of childhood. The hospital’s work is supported through funds raised by ALSAC. ALSAC covers all costs not covered by insurance for medical treatment rendered at St. Jude Children’s Research Hospital. Families without insurance are never asked to pay. For more information, please visit www.stjude.org.

Bonnie Cameron | EurekAlert!
Further information:
http://www.stjude.org/

More articles from Health and Medicine:

nachricht Investigators may unlock mystery of how staph cells dodge the body's immune system
22.09.2017 | Cedars-Sinai Medical Center

nachricht Monitoring the heart's mitochondria to predict cardiac arrest?
21.09.2017 | Boston Children's Hospital

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: The pyrenoid is a carbon-fixing liquid droplet

Plants and algae use the enzyme Rubisco to fix carbon dioxide, removing it from the atmosphere and converting it into biomass. Algae have figured out a way to increase the efficiency of carbon fixation. They gather most of their Rubisco into a ball-shaped microcompartment called the pyrenoid, which they flood with a high local concentration of carbon dioxide. A team of scientists at Princeton University, the Carnegie Institution for Science, Stanford University and the Max Plank Institute of Biochemistry have unravelled the mysteries of how the pyrenoid is assembled. These insights can help to engineer crops that remove more carbon dioxide from the atmosphere while producing more food.

A warming planet

Im Focus: Highly precise wiring in the Cerebral Cortex

Our brains house extremely complex neuronal circuits, whose detailed structures are still largely unknown. This is especially true for the so-called cerebral cortex of mammals, where among other things vision, thoughts or spatial orientation are being computed. Here the rules by which nerve cells are connected to each other are only partly understood. A team of scientists around Moritz Helmstaedter at the Frankfiurt Max Planck Institute for Brain Research and Helene Schmidt (Humboldt University in Berlin) have now discovered a surprisingly precise nerve cell connectivity pattern in the part of the cerebral cortex that is responsible for orienting the individual animal or human in space.

The researchers report online in Nature (Schmidt et al., 2017. Axonal synapse sorting in medial entorhinal cortex, DOI: 10.1038/nature24005) that synapses in...

Im Focus: Tiny lasers from a gallery of whispers

New technique promises tunable laser devices

Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

Im Focus: Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material

For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.

Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

Rainbow colors reveal cell history: Uncovering β-cell heterogeneity

22.09.2017 | Life Sciences

Penn first in world to treat patient with new radiation technology

22.09.2017 | Medical Engineering

Calculating quietness

22.09.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>